Johnson & Johnson targets earlier-line myeloma with CARVYKTI expansion
Johnson & Johnson’s CARVYKTI shows 80 percent treatment-free survival at 30 months in second-line myeloma. Is CAR-T moving to earlier use?
Johnson & Johnson’s CARVYKTI shows 80 percent treatment-free survival at 30 months in second-line myeloma. Is CAR-T moving to earlier use?